BCDIPLOMA
9.3.2022 23:12:12 CET | Business Wire | Press release
How can organisations protect against fraudulent certifications or fake English assessment test results? How can test takers in Europe receive their TOEIC ® test results in one click? How can test takers in Europe be sure that their test results are certified, tamper-proof and secure? To answer these questions, ETS Global, a subsidiary of ETS, chose to collaborate with BCdiploma, the industry-leading company for the digitisation of academic documents via blockchain technology. In Europe, ETS Global and BCdiploma are working on securing hundreds of thousands of digital TOEIC score reports via blockchain. For ETS Global, this is another step in its digital transformation. Starting from January 2022, TOEIC digital score reports are available in France and will be available across Europe during 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220223005682/en/
The result of this collaboration between these two leading players is a digital TOEIC score report that is :
- Secure: the storage of data on the blockchain makes it impossible to falsify the score report. BCdiploma complies with the strictest data protection regulations. In addition to the blockchain's encryption, BCdiploma adds its own secure, patented algorithms. This way, ETS Global and test takers retain full control over their data, which search engines cannot find or list.
- Universal: BCdiploma adapts to all consultation or sharing standards such as Verifiable Credentials from W3C and EBSI, Open Badges, EDCI, and more.
- User-friendly: available online in one click, this digitised document can be downloaded and sent by email, printed or exported in PDF format. A QR code is added to the document, which the test taker or the recipient of the certification can scan.
- Faster : because results are sent by email, test taker receive their scores faster compared to paper score report shipped by post.
- Streamlined: this digitalisation saves time for universities, schools and training organisations. The sending of results to test takers is automated. As for recruiters, they have access to a certified certificate, avoiding the need for inefficient "fact checking" to verify the authenticity of the document.
- More innovative : for the test taker, sending a secure link or a QR code of a certification guarantees quality and presents a modern picture to recruiters.
- More "carbon compatible"*: TOEIC digital score reports are issued using "Avalanche®", the latest generation and one of the most energy-efficient blockchains. Besides, stopping printing score reports will enable ETS Global to save seven trees/year. And without any paper score report to ship to test takers, ETS Global's carbon footprint will decrease by about 490kg of CO2 /year.
Miguel Membrado, Chief Digital Officer of ETS Global says: "The digitalisation of the education sector has been accelerating for years, and even more so since the start of the pandemic. Being able to offer digital TOEIC® test score reports to all ETS Global stakeholders is an obvious choice. We are delighted to be working with BCdiploma, a leading player in this field. As of today, we are offering this service to our test takers in Europe at no additional cost with the goal that within six months, the use of paper score reports in Europe will decline in favour of digital. This is not a war between digital and paper. Our customers will have the choice, of course. But we are convinced of the benefits of digitalisation to the overall customer experience, which this project perfectly illustrates."
Luc Jarry-Lacombe, CEO of BCdiploma, adds: "Our job as a software publisher is to reinvent a diploma that fits into the Digital Workplace. Better yet, it's about bringing the benefits of the blockchain system to test takers, recruiters, and all training organisations and institutions. 50% to 60% of our costs are dedicated to R&D, which enables us to deliver an impeccable service with the latest blockchain technologies. We are very happy to collaborate with the ETS Global teams, to offer more than a diploma: a real quality marketing object."
*already available in France. Deployment in Europe in 2022
About BCdiploma
BCdiploma has been trusted by more than 120 institutions, universities, and businesses in 18 countries. Our patented technology takes advantage of the latest blockchain and distributed storage technologies to deliver a high value Digital Credentials service. Our team brings to institutions a recognised expertise to succeed in their digital transformation projects. https://www.bcdiploma.com/en
About ETS Global
ETS Global B.V., a wholly owned subsidiary of ETS, is the international arm of ETS. At ETS Global B.V., we bring expertise to educational and business communities around the world, including companies, language schools, academic institutions and public service organisations. ETS Global serves 80 countries and offers a range of ETS products, services and learning solutions. https://www.etsglobal.org/fr/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005682/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom